ArticleJournal of medicinal chemistry2018

Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.

Xiaoyang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.